Moreover, while most existing in silico Mcl-1 inhibitor studies emphasize general anti-cancer utility, our work uniquely bridges prior experimental cytotoxicity data with structure-based modeling focused on AML. This evidence concerns the gene MCL1 and acute myeloid leukemia.